Armed spider bite: Difference between revisions

Line 43: Line 43:


==Disposition==
==Disposition==
 
*May discharge those with no systemic symptoms after period of ED observation
*Admit patients with signs or symptoms of systemic toxicity


==See Also==
==See Also==

Revision as of 01:57, 2 August 2021

Background

  • Identification: Brown gray with white spots forming a longitudinal band on the dorsal abdomen and a red-brown brush of hair on the chelicerae. Large in size (4.5-6cm) with 4-5mm fangs.
    • They do not form webs, but rather are mobile nocturnal hunters
    • among the largest and most aggressive spiders in South AmericaHabitat restricted to South America, largely Brazil, Argentina, and Uruguay.
  • Genus: Phoneutria
  • The best-known representative is P. nigriventer, the Brazilian Wandering Spider

Venom

  • A complex mixture of polypeptide components. Neurotoxicity is the most clinically relevant.
  • Histamine and other components potentiate localized swelling and vascular permeability
  • Several neurotoxic components that activate sodium channels, potentiating action potentials and causing uncontrolled muscle contractions.

Clinical Features

  • Initial intense pain that radiates to the trunk
  • Within 10-20 minutes, onset of systemic toxicity
    • Tachycardia
    • Hypertension
    • Profuse diaphoresis,
    • Salivation
    • Vertigo
    • Vision disturbances
    • Nausea and Vomiting
    • Priapism
  • Death has been reported, particularly in children and frail adults, from respiratory paralysis
  • Most recover in 24-48hours

Differential Diagnosis

Envenomations, bites and stings

Evaluation

  • Generally a clinical diagnosis

Management

  • Largely Supportive Care
    • Pain Control
      • Local anesthetic infiltration at site of the bite is effective in 95% of cases
      • Opiates are discouraged as they may potentiate respiratory depression in severe envenomation
  • Antivenom
    • Polyvalent and Monovalent formulations available
      • Skin testing and antihistamine ppx recommended prior to use
      • 1-5 vials given IV or IM
    • Clinical response judged by relief of pain or resolution of priapism

Disposition

  • May discharge those with no systemic symptoms after period of ED observation
  • Admit patients with signs or symptoms of systemic toxicity

See Also

External Links

References